医药品·生物科技的分销交易 (2016～2024年)

本报告提供全球医药品·生物科技市场上分销交易的缔结状况相关分析，彙整整体交易数量的转变和预测 (2016～2024年)，近几年的代表性交易案例，主要企业的交易缔结动向，各技术·各治疗领域达成交易的动向等资讯，为您概述为以下内容。

目录

摘要整理

第1章 简介

第2章 分销交易趋势

• 简介
• 分销交易定义
• 分销交易趋势 (2016年以后)
  • 分销交易趋势:各年度 (2016～2024年)
  • 分销交易趋势:各开发阶段 (2016～2024年)
  • 分销交易趋势:各产业领域 (2016～2024年)
  • 分销交易趋势:各治疗领域 (2016～2024年)
  • 分销交易趋势:各技术种类 (2016～2024年)
  • 分销交易趋势:最活跃的企业的情况 (2016～2024年)
  • 纯分销交易的属性
  • 多零组件交易上的流通属性
• 缔结商业联盟以履行分销合约

第3章 分销交易结构:概要

• 简介
• 流通契约结构
• 更广泛的联盟契约一部分的销售权

第4章 主要分销交易

• 简介
• 前几名的分销交易 (以金额为准)

第5章 分销交易:最活跃的交易缔结25企业

• 简介
• 分销交易:最活跃的交易缔结25企业

第6章 分销交易:契约的明细

• 简介
• 分销交易的契约数量 (2016～2024年)
• 交易明细
• 交易明细:流通的交易缔结，企业名 (A～Z)
• 交易明细:流通的交易缔结，各治疗领域
• 交易明细:流通的交易缔结，各技术种类

关于Wildwood Ventures

Distribution Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter distribution deals.

Fully revised and updated, the report provides details of distribution deals from 2016 to 2024.

The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of distribution deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of distribution dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals.

Chapter 4 provides a review of the leading distribution deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

The deal directory includes a comprehensive listing of all distribution deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.

Key benefits

Distribution Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse distribution deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Distribution Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.

Distribution Deals in Pharmaceuticals and Biotechnology includes:

• Trends in distribution dealmaking in the biopharma industry
• Overview of distribution deal structure
• Directory of distribution deal records covering pharmaceutical and biotechnology
• The leading distribution deals by value
• Most active distribution dealmakers
• The leading distribution partnering resources

In Distribution Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Distribution Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for distribution deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in distribution dealmaking

• 2.1. Introduction
• 2.2. Definition of distribution deals
• 2.3. Trends in distribution deals since 2016
  • 2.3.1. Distribution dealmaking by year, 2016 to 2024.
  • 2.3.2. Distribution dealmaking by phase of development, 2016 to 2024.
  • 2.3.3. Distribution dealmaking by industry sector, 2016 to 2024.
  • 2.3.4. Distribution dealmaking by therapy area, 2016 to 2024.
  • 2.3.5. Distribution dealmaking by technology type, 2016 to 2024.
  • 2.3.6. Distribution dealmaking by most active company, 2016 to 2024.
  • 2.3.7. Attributes of pure distribution deals
  • 2.3.8. Attributes of distribution in multi-component deals
• 2.4. Aligning partners to make the distribution agreement workChapter

Chapter 3 - Overview of distribution deal structure

• 3.1. Introduction
• 3.2. Distribution agreement structure
• 3.3. Distribution rights as part of a wider alliance agreement

Chapter 4 - Leading distribution deals

• 4.1. Introduction
• 4.2. Top distribution deals by value

Chapter 5 - Top 25 most active distribution dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active distribution dealmakers

Chapter 6 - Distribution deals including contracts directory

• 6.1. Introduction
• 6.2. Distribution deals with contracts 2016-2024
• Deal directory
• Deal directory - distribution dealmaking by companies A-Z
• Deal directory - distribution dealmaking by therapy area
• Deal directory - distribution dealmaking by technology type

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of distribution
• Figure 2: Trends in distribution deal announcements, 2016 to 2024
• Figure 3: Distribution deals signed at each phase of development, 2016 to 2024
• Figure 4: Distribution deals by industry sector, 2016 to 2024
• Figure 5: Distribution deals by therapy area, 2016 to 2024
• Figure 6: Distribution deals by technology type, 2016 to 2024
• Figure 7: Top 25 most active distribution dealmakers, 2016 to 2024
• Figure 8: Issues in implementing distribution agreements
• Figure 9: Distribution agreements - what should a contract include?
• Figure 10: Components of the distribution deal structure
• Figure 11: Top distribution deals by value 2016 to 2024
• Figure 12: Most active distribution dealmakers 2016 to 2024